NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference
LAWRENCE, Mass., Aug. 1, 2014 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, and Mathew Towse, Chief Financial Officer, will present at the 34th Annual Canaccord Genuity Growth Conference being held at the InterContinental in Boston, MA, on Wednesday, August 13th at 4:30 p.m. ET. A webcast of the event will be made available at http://ir.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to Messrs. Burbank and Towse's plans to present at this conference. NxStage specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.
Kristen K. Sheppard, Esq.
VP, Investor Relations
SOURCE NxStage Medical Inc.